Devyser Diagnostics AB Cash Flow Conversion Efficiency
Devyser Diagnostics AB cash flow conversion efficiency. Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has a cash flow conversion efficiency ratio of 0.032x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr12.30 Million ≈ $1.32 Million USD) by net assets (Skr381.00 Million ≈ $41.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Devyser Diagnostics AB (2018–2025)
Cash flow conversion efficiency of Devyser Diagnostics AB from 2018 to 2025. This chart illustrates how Devyser Diagnostics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Devyser Diagnostics AB stock price today for real-time trading data and today's change.
Devyser Diagnostics AB Cash Flow Conversion Ratio Explained
Devyser Diagnostics AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Devyser Diagnostics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Devyser Diagnostics AB ranked by their cash flow conversion efficiency. Also see Devyser Diagnostics AB market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Diploma PLC
LSE:DPLM
|
0.105x |
|
GOLCONDA GOLD LTD
F:Y87
|
0.075x |
|
Atp Ticari Bilgisayar Agi ve Elektrik Guc Kaynaklari Uretim Pazarlama ve Ticaret
IS:ATATP
|
-0.291x |
|
Fonar Corporation
NASDAQ:FONR
|
0.001x |
|
Shanghai Haixin Group Co Ltd B
SHG:900917
|
0.001x |
|
Kc Cottrell
KO:119650
|
-0.341x |
|
Sunko Ink Co Ltd
TW:1721
|
0.009x |
|
Norsk Titanium AS
OL:NTI
|
-0.732x |
Annual Cash Flow Conversion Efficiency for Devyser Diagnostics AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Devyser Diagnostics AB from 2018 to 2025. Review DVYSR free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr354.30 Million ≈ $38.13 Million |
Skr8.20 Million ≈ $882.45K |
0.023x | +117.26% |
| 2024-12-31 | Skr349.00 Million ≈ $37.56 Million |
Skr-46.80 Million ≈ $-5.04 Million |
-0.134x | +25.91% |
| 2023-12-31 | Skr385.10 Million ≈ $41.44 Million |
Skr-69.70 Million ≈ $-7.50 Million |
-0.181x | -92.80% |
| 2022-12-31 | Skr431.44 Million ≈ $46.43 Million |
Skr-40.50 Million ≈ $-4.36 Million |
-0.094x | -137.32% |
| 2021-12-31 | Skr416.68 Million ≈ $44.84 Million |
Skr-16.48 Million ≈ $-1.77 Million |
-0.040x | -294.14% |
| 2020-12-31 | Skr30.77 Million ≈ $3.31 Million |
Skr627.00K ≈ $67.48K |
0.020x | -94.85% |
| 2019-12-31 | Skr37.01 Million ≈ $3.98 Million |
Skr14.63 Million ≈ $1.57 Million |
0.395x | +96.80% |
| 2018-12-31 | Skr29.97 Million ≈ $3.23 Million |
Skr6.02 Million ≈ $647.85K |
0.201x | -- |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more